您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > GLPG0634
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
GLPG0634
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
GLPG0634图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
25mg电议
100mg电议

产品介绍
GLPG0634 (GLPG0634) 是一种具有口服活性的选择性 JAK1 抑制剂,对 JAK1、JAK2、JAK3 和 TYK2 的 IC50 分别为 10 nM、28 nM、810 nM 和 116 nM。

Cell lines

THP-1 cells (ATCC TIB-202)

Preparation method

The solubility of this compound in DMSO is >21.3mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

1 μM

Applications

In THP-1 cells, GLPG0634 preferentially inhibited JAK signaling complexes containing JAK1 and also inhibited Th1 differentiation with similar potencies of 1 μM or lower.

Animal models

Male Sprague Dawley rats (180–200 g) and CD1 mice (23–25 g)

Dosage form

orally dosed as a single esophageal gavage at 5 mg/kg (dosing volume of 5 ml/kg) and i.v. dosed as a bolus via the caudal vein at 1 mg/kg (dosing volume of 5 ml/kg)

Application

GLPG0634 dose-dependently reduced inflammation, cartilage, and bone degradation in the CIA model in rats and mice with significant effect of 3 mg/kg. Protection from bone damage was evidenced by a dose-dependent reduction, with significant effect from GLPG0634 (3 mg/kg), showed a marked reduction of the infiltration of inflammatory cells while protecting the articular cartilage and bone from 1 mg/kg onward.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

GLPG0634 is a selective inhibitor of JAK1 with IC50 value of 10nM [1].

GLPG0634 is a small molecule inhibitor of JAK1. It shows potent inhibitory activity against both JAK1 and JAK2 with IC50 values of 10nM and 28nM, respectively. In cellular assays, GLPG0634 is most potent in inhibiting the JAK1/JAK3/γc signaling induced by IL-2– and IL-4 as well as the JAK1/TYK2 type II receptor signaling induced by IFN-αB2. However, it shows lower potent to inhibit JAK2 homodimer–mediated signaling induced by EPO or PRL. It demonstrates that GLPG0634 is specific to JAK1. In addition, GLPG0634 is found to inhibit the phosphorylation of STAT1 and STAT5 induced by cytokines. Moreover, GLPG0634 inhibits the differentiation of Th1 and Th2 cells with similar potencies. Th17 differentiation is also affected by GLPG0634 with a lower potency [1].

In the rat model of collagen-induced arthritis (CIA), oral administration of GLPG0634 shows a marked protection from bone damage at dose of 3 mg/kg. It reduces the infiltration of inflammatory cells significantly from 1 mg/kg onward [1].

References:
[1] Van Rompaey L, Galien R, van der Aar E M, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. The Journal of Immunology, 2013, 191(7): 3568-3577.